Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; magnesium stearate; iron oxide red - hypertension: linopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: linopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that linopril tablets be administered with a diuretic. acute myocardial infarction: linopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. linopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; iron oxide red; maize starch; mannitol - hypertension: linopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: linopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that linopril tablets be administered with a diuretic. acute myocardial infarction: linopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. linopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; magnesium stearate; maize starch; iron oxide red - hypertension: linopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: linopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that linopril tablets be administered with a diuretic. acute myocardial infarction: linopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. linopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 2.5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; mannitol; maize starch - hypertension: linopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: linopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that linopril tablets be administered with a diuretic. acute myocardial infarction: linopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. linopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; magnesium stearate; iron oxide red - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; iron oxide red; maize starch; mannitol - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; magnesium stearate; maize starch; iron oxide red - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 2.5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; mannitol; maize starch - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - lisinopril - oral tablet - 5mg

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - lisinopril dihydrate, quantity: 22.22 mg (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: mannitol; calcium hydrogen phosphate dihydrate; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; iron oxide red; iron oxide black; iron oxide yellow - hypertension: lisinopril hexal is indicated in the treatment of mild to moderate essential hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have nor been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: lisinopril hexal is also indicated in the treatment of heart failure. in such patients, it is recommended the lisinopril hexal be administered together with a diuretic. acute myocardial infarction: lisinopril hexal is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril hexal may be initiated within 24 hours of an acute myocardial infarction.